红霉素抗过敏性气道炎症机制的探讨

被引:12
作者
贺建新
赵顺英
江载芳
机构
[1] 首都医科大学附属北京儿童医院呼吸功能室,首都医科大学附属北京儿童医院呼吸功能室,首都医科大学附属北京儿童医院呼吸功能室,,
关键词
红霉素; NF-κB; 气道炎; 大鼠,Sprague-Dawley;
D O I
暂无
中图分类号
R725.6 [小儿呼吸系及胸部疾病];
学科分类号
100202 ;
摘要
目的 探讨红霉素是否对大鼠过敏性气道炎症具有保护作用以及是否通过抑制转录因子NF-κB的活性来达到抗炎效果。方法 用鸡卵清白蛋白 (OVA)腹腔注射一次致敏SD雄性大鼠,同时佐以氢氧化铝和百日咳杆菌, 2周后雾化吸入 1%的OVA进行激发,连续激发 7天,成功制作大鼠过敏性气道炎症模型。治疗干预组动物OVA激发的同时口服红霉素 [180mg/(kg·d) ]。最后一次激发后 24h处死大鼠,留取标本进行检测。用支气管肺泡灌洗液 (BALF)和肺组织病理分析的方法检测肺组织炎症;用免疫组织化学的方法检测核因子 kappaB(nuclearfactorkappaB, NF-κB)亚单位p65在细胞核内的表达;用凝胶电泳迁移改变分析的方法检测肺组织NF κB的结合活性。结果 肺组织病理切片显示红霉素治疗干预组肺组织炎症细胞浸润的范围较模型组明显减小。红霉素干预组BALF中白细胞总数为 (31±22)×108 /L,模型组为 (66±28)×108 /L(P<0.01 )。红霉素干预组主支气管黏膜下层单位面积内细胞核表达NF κB阳性的细胞数为 (1.4±0.4)×103 个 /mm2,模型组为(2.6±0.6)×103 个 /mm2 (P<0.01)。红霉素干预组动物肺组织转录因子NF-κB结合活性(32±14)低于模型组(46±17 ) (P<0.05 )。结论 红霉素干预组BALF中白细胞总数较模型组降低,主支气管黏膜下层单
引用
收藏
页码:40 / 42
页数:3
相关论文
共 11 条
[1]  
Transcription factors. Papavassiliou AG. The New England Journal of Medicine . 1995
[2]  
New evidence of inflammation in asthma. Vignola AV,Gagliardo R,Guerrera D,et al. Thorax . 2000
[3]  
Ozone-induced IL-8 expression and transcription factor binding in respiratory epithelial cells. Jaspers I,Flescher E,Chen LC. American Journal of Physiology . 1997
[4]  
The allergen Der p1 induced NF-B activation through interference with IB alpha function in asthmatic bronchial epithelial cells. Stacey MA,Sun G,Vassalli G,et al. Biochemical and Biophysical Research Communications . 1997
[5]  
Activation and localization of transcription factor, nuclear factor-kappa B in asthma. Hart L A,Krishnan V L,Adcock I M, et al. American Journal of Respiratory and Critical Care Medicine . 1998
[6]  
Nuclear factor-B: a pivotal transcription factor in chronic inflammatory disease. Barnes PJ,Karin M. The New England Journal of Medicine . 1997
[7]  
Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Amayasu H,Yoshida S,Ebana S,et al. Annals of Allergy Asthma Immunology . 2000
[8]  
Rhinovirus stimulation of interkin-6 in vivo and in vitro: evidence for nuclear factor B-dependent transcriptional activation. Zhu Z,Tang W,Ray A,et al. The Journal of Clinical Investigation . 1996
[9]  
Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Miyatake H,Taki F,Taniguchi H,et al. Chest . 1991
[10]  
The use of macrolide antibiotic substances in the treatment of asthma. Itkin IH,Menzel ML. The Journal of Allergy and Clinical Immunology . 1970